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OBJECTIVE — Insulinpumptherapy(continuoussubcutaneousinsulininfusion[CSII])and
multipledailyinjections(MDIs)withinsulinglargineasbasalinsulinandmealtimeinsulinlispro
have not been prospectively compared in people naïve to either regimen in a multicenter study.
We aimed to help close that deﬁciency.
RESEARCH DESIGN AND METHODS — People with type 1 diabetes on NPH-based
insulin therapy were randomized to CSII or glargine-based MDI (both otherwise using lispro)
andfollowedfor24weeksinanequivalencedesign.Fiftypeoplewerecorrectlyrandomized,and
43 completed the study.
RESULTS — Total insulin requirement (mean  SD) at end point was 36.2  11.5 units/day
on CSII and 42.6  15.5 units/day on MDI. Mean A1C fell similarly in the two groups (CSII
0.7  0.7%; MDI 0.6  0.8%) with a baseline-adjusted difference of 0.1% (95% CI 0.5
to 0.3). Similarly, fasting blood glucose and other preprandial, postprandial, and nighttime
self-monitored plasma glucose levels did not differ between the regimens, nor did measures of
plasma glucose variability. On CSII, 1,152 hypoglycemia events were recorded by 23 of 28
participants (82%) and 1,022 in the MDI group by 27 of 29 patients (93%) (all hypoglycemia
differences were nonsigniﬁcant). Treatment satisfaction score increased more with CSII; how-
ever, the change in score was similar for the groups. Costs were 3.9 times higher for CSII.
CONCLUSIONS — In unselected people with type 1 diabetes naïve to CSII or insulin
glargine, glycemic control is no better with the more expensive CSII therapy compared with
glargine-based MDI therapy.
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I
nsulinsubstitutionintype1diabetesis
based on mealtime rapid-acting and
basal insulin, using multiple daily in-
jections(MDIs)orcontinuoussubcutane-
ousinsulininfusion(CSII)(1,2).Inmeta-
analyses of studies, two small trials (3,4)
with the long-acting insulin analog insu-
lin glargine suggested superiority of CSII
over MDI in terms of A1C lowering.
Lower A1C levels and less hypoglycemia
with CSII were also recently reported by
Hoogmaetal.(5)inalargetype1diabetes
population (272 people) comparing CSII
with MDI using NPH insulin. A more re-
cent meta-analysis (6) proposed that CSII
is beneﬁcial to “selected” people (people
with recurrent and frequent severe hypo-
glycemiaonMDIusingNPHinsulin)with
type 1 diabetes.
Since 2000, the long-acting insulin
analogs, insulin glargine and insulin det-
emir, have become available (2). These
are progressively replacing NPH insulin
as basal insulin in type 1 diabetes due to
favorable pharmacokinetics and pharma-
codynamics, namely, a less pronounced
peak concentration and longer duration
of action (7,8) resulting in lower A1C lev-
els and less hypoglycemia (9,10). Addi-
tionally, the long-acting analogs may give
more reproducible effects compared with
NPH insulin (11,12).
This better glycemic control with the
new analogs has reopened the question of
comparisons between CSII and MDI
based on long-acting analogs, rather than
NPH insulin. A number of studies have
attempted to compare CSII with MDI us-
ing insulin glargine, but not insulin det-
emir, as basal insulin (13–17). However,
these studies are small, nonrandomized,
or of short duration.
The aim of the present prospective,
randomized, multicenter, international
study was to assess the difference in gly-
cemic control when people with type 1
diabetes using NPH insulin-based MDIs
are randomized either to an MDI regimen
with insulin glargine as basal insulin and
mealtime insulin lispro or to continuous
subcutaneous infusion of insulin lispro
and managed on either regimen for 6
months.
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METHODS— Our primary objective
was to investigate whether an MDI regi-
menusinginsulinglargineasbasalinsulin
with insulin lispro at mealtimes can
achieve glycemic control (A1C) equiva-
lenttoCSII(insulinlispro)inpeoplewith
type 1 diabetes. Secondary objectives
were to compare other measures of blood
glucose control (pre- and postprandial,
bedtime and 0300 h levels, and within-
day glucose variability), hypoglycemia,
adverseevents(AEs),treatmentcosts,and
treatment satisfaction.
This was a randomized, parallel-
group, open-label, multicenter (n  5)
studyperformedinthreeEuropeancoun-
tries with a 1-week run-in period fol-
lowed by a 24-week treatment period
(including 4 weeks of active dose titra-
tion), with clinic visits at 0, 2, 8, 16, and
24 weeks and 2 weeks follow-up. An
open-label design was necessary owing to
the different insulin administration regi-
mens. Concealed remote randomization
was by an online system. Ethical approval
was by local procedures, and all partici-
pantsprovidedwritteninformedconsent.
The study was performed according to
Good Clinical (Research) Practice/
Declaration of Helsinki.
Participants were aged 18–70 years,
with a BMI 27.0 kg/m
2 and diabetes for
1 year, A1C 6.5–9.0%, fasting plasma
glucose (FPG) 7.0 mmol/l (126 mg/
dl), and fasting plasma C-peptide 0.10
nmol/l at the screening visit. Participants
withameandurationoftreatmentof18.4
(CSII) and 20.7 (MDI) years, who were
currently using an MDI regimen with
NPHinsulin,wererecruitedandrandom-
ized. Participants were excluded if they
were prior users of CSII or insulin
glargine, were unwilling or unable to use
CSII or MDIs, had more than two severe
hypoglycemic events in the previous 6
months,orhadrecentdiabeticketoacido-
sis or impaired hepatic/renal function.
Study treatments
Randomization was to insulin glargine
(LANTUS, once daily in the evening;
sanoﬁ-aventis, Paris, France) plus meal-
timeinsulinlispro(Humalog,three-times
daily; Eli Lilly, Indianapolis, IN) or to in-
sulin lispro administered subcutaneously
using a MiniMed 508 pump (MiniMed
Technologies, Northridge, CA). Insulin
dosetitrationwastothesameglucosetar-
gets on both treatments: FPG 4.4–6.6
mmol/l (80–120 mg/dl), other prepran-
dial blood glucose 5.0–7.7 mmol/l (90–
140 mg/dl), 2-h postprandial blood
glucose 7.7 mmol/l (140 mg/dl), and
bedtime blood glucose 6.1–8.3 mmol/l
(110–150 mg/dl).
Insulinglarginewasstartedaccording
to prior basal insulin dose. Titration was
based on the mean FPG over at least 3
days, adjusted by 2 units if FPG was
6.6–8.8 mmol/l (120–160 mg/dl), 4
units if FPG was 8.8–11 mmol/l (160–
200 mg/dl), or 2 units if FPG was 4.4
mmol/l (80 mg/dl). Further titration of
the dose was performed at investigator
discretionifsymptomsconsistentwithse-
vere hypoglycemia occurred. The initial
insulin lispro dose was investigator se-
lected, based on prior mealtime doses,
and was titrated once basal insulin dose
was optimized. The insulin lispro dose
was adjusted by 1–2 units, as appropri-
ate. Initiation of CSII was based on the
pump manufacturer’s recommendations,
using the “normal bolus option”; a bolus
wizard calculator was not used. Infusion
sites were advised to be changed every
2–3 days in accordance with investiga-
tors’ routine clinical practice and manu-
facturer’s recommendations.
Study measurements
AnalysisofA1Cwasperformedatacen-
tral laboratory (Diabetes Control and
Complications Trial [DCCT] Research
Group aligned) at screening and weeks
8, 16, and 24. Participants were asked
to perform self-monitored plasma glu-
cose measurements four times daily
(bedtime and preprandial) using a plas-
ma-calibrated memory glucose meter
(OneTouch Ultra; Lifescan, Milpitas,
CA). Eight-point proﬁles (pre-/
postprandial,bedtime,0300h)werere-
questedon3days(including1weekend
day) in the 2-week period prior to each
study visit. All results were diary re-
corded.Participantswereaskedtocom-
plete Diabetes Treatment Satisfaction
Questionnaires (DTSQs) (status DTSQ
and change DTSQ) (18) at randomiza-
tion and week 24.
The costs of treatment were calcu-
lated in euros (€) based on the cost of
therapies, devices, and consumables.
Equipment costs include the glucose
meters and consumables (lancets and test
strips), insulin pens and consumables
(needles), and insulin pumps and con-
sumables (batteries, and infusion sets).
Thepumpacquisitioncostwasamortized
over 5 years. The costs of insulin were
calculated by two methods: insulin dis-
pensed and insulin used. Insulin dis-
pensed was based on the entire cost of
treatment, including wastage according
to dispensing records (based on phar-
macy and investigator dispensing
records); insulin used was based on insu-
lin doses recorded in treatment diaries by
participants.
Hypoglycemia was recorded in dia-
ries and extracted at study visits. Nonse-
vere hypoglycemia was deﬁned as
symptoms consistent with hypoglycemia
not requiring the assistance of another
person and conﬁrmed by plasma glu-
cose 4.0 mmol/l (72 mg/dl); severe
hypoglycemia was deﬁned as similar
symptoms but requiring management
assistance and either plasma glucose
2.0 mmol/l (36 mg/dl) or prompt
recovery after oral or intravenous car-
bohydrateorglucagon;nocturnalhypo-
glycemia was deﬁned as between
bedtime and rising. Other AEs were
collected by direct questioning at
study visits. Unprogrammed changes of
CSII or injection equipment were also
captured.
Statistical analyses
Sixty randomized individuals were esti-
mated to give 80% power, after 15%
dropout, to demonstrate equivalence at
0.6% A1C at a mean A1C of 7.0% and
anSDof0.7%.ANCOVA,withcenterand
group as the ﬁxed variables and baseline
values as covariates, was used for contin-
uous variables. The Cochran-Mantel-
Haenszel test, stratiﬁed by center, was
used for discrete end points. Two-sided
95% CIs for treatment differences were
calculated without adjustment for multi-
ple end points. Safety measures and ad-
verse effects were compared between
treatmentgroupsusingtheWilcoxontest.
Data were summarized as means  SD or
means (95% CI). The mean amplitude of
glycemic excursion was calculated from
the eight-point plasma glucose proﬁles.
All results are presented for the per-
protocol population as is appropriate for
an equivalence study to minimize bias.
This population included all randomized
participants treated with at least one dose
of study insulin and without a major pro-
tocol deviation that would interfere with
treatment efﬁcacy. An intent-to-treat
(ITT) analysis (all randomized patients)
was also performed as a secondary analy-
sis. Safety and hypoglycemia were re-
ported for all participants who took at
least one dose of study insulin and pro-
vided follow-up data (safety population).
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Study population
Of 67 people screened, 58 met inclusion
criteria and were randomized: 28 to CSII
and 30 to MDI. One participant was ran-
domized in error and was not treated. Of
57 patients treated, 7 were protocol vio-
lators, 1 had a baseline A1C 9.0%, 1
had previously used insulin glargine/
CSII, 1 had no C-peptide status, and 4
had used corticosteroids/glucocorticoids.
Therefore, the population analyzed (per-
protocolpopulation,n50)included24
patients in the CSII group and 26 in the
MDI group (Table 1); the ITT and safety
analysiscomprised57patients(screening
failures excluded). Seven participants
dropped out before completion—three
withdrawing consent, one due to an AE,
one due to pregnancy, and two due to
protocol noncompliance. Baseline char-
acteristics were similar for both treatment
groups (Table 1).
Insulin dose
In the CSII group after randomization,
basal and prandial doses were 17.2  8.5
and 17.4  6.7 units/day, respectively
(total: 34.6  13.0 units/day), and at 24
weeks 18.2  8.0 and 18.0  6.1 units/
day, respectively (total: 36.2  11.5
units/day). In the MDI group after ran-
domization, basal and prandial doses
were 19.6  6.3 and 25.7  12.0 units/
day, respectively (total: 45.3  15.0
units/day), and at 24 weeks 22.5  7.0
and 20.1  9.8 units/day, respectively
(total: 42.6  15.5 units/day). Similar
changes in insulin dose were observed for
the ITT population.
Blood glucose control
AsimilardecreaseinA1Cfrombaselineto
endpointwasobservedinthetwogroups
(Fig. 1A): 0.7  0.7% on CSII and
0.6  0.8% on MDI, with a baseline-
adjusted difference of 0.1% (95% CI
0.5 to 0.3). Mean blood glucose de-
creased in both treatment groups (Table
2) (Fig. 1), with a difference of 0.03
mmol/l (0.8 to 0.8) (0.6 mg/dl [13.5
to 14.7]). The primary efﬁcacy results for
the ITT population were similar.
Fasting blood glucose levels im-
proved in both groups (Table 2), with a
difference of 0.7 mmol/l (95% CI 1.8
to 0.5) (12.3 mg/dl [–32.9 to 8.2]). Co-
efﬁcient of variation (CV) of fasting blood
glucose was unchanged (CSII from 41 
12 to 42  13%; MDI from 43  18 to
45  12%) and did not differ between
groups (difference: 2.4% [9.5 to
4.7]). Preprandial blood glucose levels
decreasedinbothgroups(Table2),witha
treatment difference of 0.9 mmol/l
(2.3 to 0.4) (17.1 mg/dl [–42.1 to
8.0]). Postprandial blood glucose levels
decreasedintheCSIIgroupandincreased
in the MDI group (Table 2) but with no
statistically signiﬁcant differences be-
tween groups (difference: 0.3 mmol/l
[1.1 to 1.7]) (5.5 mg/dl [–18.9 to
29.9]). At 0300 h, plasma glucose in-
creased with both CSII and MDI treat-
ment (Table 2), with a treatment
difference of 3.0 mmol/l (0.4 to 6.5)
(54.8 mg/dl [–7.2 to 116.7]).
Baseline and end point eight-point
blood glucose proﬁles are shown in Fig.
1BandC.TheCVoftheeight-pointblood
glucoseproﬁledecreasedfrom5310to
46  8% (CSII) and from 52  12 to
47  11% (MDI), a treatment difference
of 1.4% (95% CI 6.6 to 3.7). The
mean amplitude of glycemic excursion
decreased similarly in both groups (Table
2), with a treatment difference of 0.4
mmol/l(1.8to1.0)(7.1mg/dl[–31.9
to 17.8]). The ITT population was com-
parable with the per-protocol results for
all secondary end points of blood glucose
control.
Hypoglycemia
On CSII, 1,152 hypoglycemic events
were recorded by 23 of 28 participants
(82%), and in the MDI group 1,022 hy-
poglycemiceventswererecordedby27of
29 participants (93%). The incidence of
hypoglycemia was similar with CSII and
MDI for overall (41  43 vs. 35  35
events/patient; P  0.93), nonsevere
(35  37 vs. 31  32 events/patient; P 
0.97), nocturnal (3  5 vs. 5  7 events/
patient;P0.34),symptomatic(1312
vs.1415events/patient;P0.84),and
asymptomatic (1.2  2.0 vs. 1.4  2.3
events/patient; P  0.95) hypoglycemia.
Two participants in both groups experi-
enced one severe hypoglycemic event.
Number of events by visit is shown in
Fig. 1D.
Treatment satisfaction
The DTSQ treatment satisfaction score
(SD)increasedfrom22.88.1atbase-
line to 31.5  4.9 at 24 weeks in the CSII
group and from 24.0  6.3 to 28.8  5.4
in the MDI group (treatment difference:
3.1 [95% CI 0.1–6.1]; P  0.042). Dif-
ferences between treatment groups re-
garding perception of hyperglycemia and
hypoglycemiawerenotstatisticallysignif-
icant. At 24 weeks, change DTSQ values
of 13.3  5.3 (CSII) and 12.9  4.9
(MDI) were observed (difference: 0.4
[2.4 to 3.3]), with no statistical differ-
ence between groups in perception of hy-
perglycemia and hypoglycemia. Results
of the ITT analyses were comparable.
Costs
Atthetimeofstudyconduct,theunitcost
of insulin for CSII was €0.021 and for
prandial and basal insulin on MDI was
€0.024 and €0.025, respectively. The av-
eragecostofinsulindispensedpersubject
was €295 for CSII (range 131–657) and
€293 for MDI (€127 prandial and €166
basal) (range 211–755). The average cost
of insulin used per participant in the
study based on diaries was €140 for CSII
(range 76–283) and €212 for MDI (€96
Table 1—Baseline characteristics of the people with type 1 diabetes studied (per-protocol
population)
CSII (n  24)* MDI (n  26)†
n (men/women) 13/11 14/12
Age (years) 37.6  12.3 42.4  9.9
Body weight (kg) 70.1  11.6 70.8  10.5
BMI (kg/m
2) 23.8  2.7 24.3  1.9
Duration of diabetes (years) 18.5  8.4 20.9  10.6
Age at diagnosis (years) 19.1  10.8 21.5  11.5
Duration of treatment (years) 18.4  8.5 20.7  10.5
Prior insulin dose (units/day)‡
Basal 20.2  12.7 20.0  7.5
Total 51.0  15.7 51.2  16.8
A1C (%) 7.7  0.7 7.8  0.6
DataaremeansSD.Theper-protocolpopulationconsistedofpatientswhowerecorrectlyrandomizedand
receiving study insulin. *Insulin lispro; †insulin glargine plus prandial insulin lispro; ‡prerandomization
dose.
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135–444).
The average cost per treatment dur-
ing the study, including all items of
equipment and dispensed insulin, was
3.9 times higher for insulin lispro–
based CSII versus MDI (€3,020 vs.
€778, respectively), including the cost
of the pump and cannula insertion kits
(see online appendix Table 1 [available
at http://dx.doi.org/10.2337/dc08-1874]).
Safety proﬁle
A total of 115 AEs were reported, 1 of
which was not treatment emergent.
Therefore, a total of 18 patients experi-
enced 59 treatment-emergent AEs in the
CSII group, and 22 patients experienced
56 treatment-emergent AEs in the MDI
group. One patient in the MDI group
withdrew due to an AE (skin rash) and
one due to pregnancy. Two individuals
on CSII each reported one serious AE
(both of severe hypoglycemia).
Three participants from three centers
had pumps replaced once, as soon as
failure was suspected. However, no me-
chanical failure was detected by the
manufacturer in these cases. Twenty in-
stances of giving set occlusion were re-
ported for nine participants from ﬁve
centers. Seven patients had one occlusion
reported; one of these later experienced
twoadditionaleventsandhadsixchanges
ofthegivingsetasapreventativemeasure
due to an episode of infection at the infu-
sion site (not recorded as occlusion
events); one participant had two events,
and one reported nine events.
CONCLUSIONS — This study sug-
gests that the optimization of basal NPH
insulinreplacementwithinsulinlisproby
CSII or an MDI-based regimen of once-
daily insulin glargine plus insulin lispro
results in similar improvement of glyce-
miccontrolinpeoplewithtype1diabetes
who are naïve to either treatment regi-
men. Both regimens achieved similar im-
provements in A1C, self-monitored
plasma glucose, and hypoglycemia.
The best estimate of difference be-
tween the regimens is 0.1% A1C, but
studypowerimpliesthattheactualdiffer-
Figure1—A:DataarethechangeinA1C(%)frombaselineoverthecourseofthestudyintheper-protocolpopulationwithtype1diabetesmanaged
with CSII with insulin lispro (insulin pump therapy) or insulin glargine plus insulin lispro MDI therapy.   , CSII; f, MDI. B: Data are the mean
eight-pointbloodglucoseproﬁlesatbaselineandendpointoverthecourseofthestudyforpeopleintheper-protocolpopulationrandomizedtoinsulin
glargineplusinsulinlisproMDItherapy.  ,baseline;f,endpoint.C:Dataarethemeaneight-pointbloodglucoseproﬁlesatbaselineandendpoint
over the course of the study for people in the per-protocol population randomized to CSII with insulin lispro (insulin pump therapy).   , baseline; f,
end point. D: Data are the number of hypoglycemic events by visit for the two insulin regimens (safety population).   , CSII; f, MDI.
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of 0.5% and an MDI advantage of 0.3%.
The present study is limited by the num-
ber of participants and a duration of 6
monthsbuthastheadvantageofbeingthe
ﬁrst prospective, multicenter study dem-
onstrating noninferiority of the insulin
glargine–based regimen versus CSII. An-
other possible limitation of the present
study is that the MiniMed 508 pump,
rather than the recent Paradigm 522 or
722 pump with the bolus wizard, was
used. The latter pumps might be helpful
to estimate bolus doses by calculating the
insulin-to-carbohydrate ratio, insulin
sensitivity factor, target blood glucose,
and insulin on board (putative length of
action of insulin bolus). However, ran-
domized, controlled trials are required in
the adult population to prove these ben-
eﬁts. In addition, an expert system might
prove useful in MDI as well.
Themeanend-of-studyA1Clevelsfor
bothregimenswereclosetoAmericanDi-
abetes Association targets and were simi-
lar to those in the intensive arm of the
DCCT trial (1,19). Although the baseline
levels were higher on NPH insulin regi-
mens, the present study did not examine
the use of NPH insulin and the fall from
baseline may have been a study effect,
though consistent with previous compar-
isons of CSII and insulin glargine–based
MDI with NPH insulin–based MDI
(16,17). However, NPH insulin regimens
can be optimized by multiple NPH insu-
lin injections (20).
As expected, intensiﬁcation of blood
glucose control and careful recording re-
sulted in increased reported rates of non-
severe hypoglycemia with no difference
between regimens. Severe hypoglycemia
was rare, but the inclusion criteria ex-
cluded people prone to this problem.
OthershavenotedthattheDCCT-derived
conclusion of an increase in severe hypo-
glycemia is not necessarily reproduced
when intensive insulin therapy is based
on insulin analogs (9,10).
Although blood glucose control with
CSIIandinsulinglargine–basedMDIwas
similarbyothermeasures,plasmaglucose
predinner was higher with the latter reg-
imen. This elevation in blood glucose in
the late afternoon hours on an insulin
glargine–based MDI regimen has been
noted previously (21). In some people
with type 1 diabetes, the duration of ac-
tion of insulin glargine appears to be 24
h. However, continued food absorption
beyond the duration of action of the
lunchtime insulin may be another cause
of predinner hyperglycemia, as the phe-
nomenon is attenuated when lunch is
skipped (21). With CSII it is possible that
this was counteracted by higher basal
ratesintheafternoon,butthesedatawere
not collected. With insulin glargine, an
additional bolus of rapid-acting analog
2–3 h after lunch can be given (21); this
wasnotpartoftheprotocolofthepresent
study. Interestingly, the theoretical ad-
vantage of multiple basal rates with CSII
did not translate into lower basal plasma
glucose levels at other times of day (Fig.
1C). Furthermore, this study conﬁrms
that the magnitude of any “dawn phe-
nomenon”ismodestwhenbasalinsulinis
optimally replaced with either CSII or an
insulin glargine regimen (22).
In the present study, glucose variabil-
ity with CSII and insulin glargine–based
MDI was not different. A previous study
(23) that compared people on long-term
CSII with those switched to insulin
glargine–basedMDIfoundasmalladvan-
tage of CSII in glucose variability, despite
no difference in overall glycemic control.
However, the importance of variability of
blood glucose when A1C, hypoglycemia,
and plasma glucose proﬁle are identical is
doubtful. Other data support the impor-
tance of glucose variability for vascular
complications in diabetes, but clinical
studies have yet to conﬁrm this (24).
That the costs of CSII are higher than
Table 2—Summary of blood glucose control results (per-protocol population)
Parameter CSII MDI Difference at end point (95% CI)
A1C (%)
Baseline 7.7  0.7 7.8  0.6
End point 7.0  0.8 7.2  0.7 0.1 (0.5 to 0.3)
SMBG mmol/l (mg/dl)	
Fasting
Baseline 10.1  3.3 (183  60) 10.4  3.2 (188  57)
End point 6.8  1.7 (123  30) 7.7  2.4 (139  43) 0.7 (1.8 to 0.5)
Preprandial
Baseline 7.8  3.6 (140  64) 8.0  3.0 (145  53)
End point 6.7  2.4 (120  43) 7.7  2.4 (138  42) 0.9 (2.3 to 0.4)
Postprandial
Baseline 8.4  3.6 (151  66) 6.9  2.6 (125  47)
End point 8.2  2.3 (147  42) 7.6  2.1 (136  39) 0.3 (1.1 to 1.7)
0300 h blood glucose mmol/l (mg/dl)	
Baseline 8.4  4.8 (151  87) 7.8  5.0 (141  90)
End point 8.8  2.3 (158  42) 8.1  4.3 (146  78) 3.0 (0.4 to 6.5)
Blood glucose mmol/l (mg/dl)	
Baseline 9.1  2.3 (164  41) 8.9  1.6 (160  30)
End point 8.1  1.8 (146  32) 8.0  1.1 (144  20) 0.03 (0.7 to 0.8)
MAGE mmol/l (mg/dl)	
Baseline 8.0  2.4 (144  43) 7.6  1.7 (137  31)
End point 6.4  2.2 (115  40) 6.4  2.1 (115  38) 0.4 (1.8 to 1.0)
Data are means  SD unless otherwise indicated. The per-protocol population consisted of patients who were correctly randomized and receiving study insulin.
MAGE, mean amplitude of glycemic excursion; SMBG, self-monitored blood glucose.
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costs of pumps and infusion sets. There
will also be a small saving in any market
where insulin glargine is more expensive
than insulin lispro. In economic terms,
withsimilarefﬁcacybuthighercosts,CSII
is “dominated” by MDI. The National In-
stitute for Health and Clinical Excellence
(U.K.) calculated a higher cost in the or-
derof€1,392to€1,772peryear,compat-
ible with our results (25).
The present study adds to previous
observations (14,15,17) of the noninferi-
ority of insulin glargine–based MDI ver-
sus CSII in different study designs. A
similar conclusion to ours was recently
reported (23) in a study in which people
with type 1 diabetes were transferred
fromlong-termCSIIinitiatedprimarilyin
the NPH insulin era to insulin glargine–
based MDI. Thus, it is likely that the ma-
jority of people with type 1 diabetes who
started CSII in the NPH insulin era did so
duetothepoorperformanceofbasalNPH
insulin. Similarly, it is likely that the ma-
jority of these people might today switch
to MDI based on insulin glargine with no
deterioration of blood glucose control
(23).
While the conclusions of the present
study establish noninferiority of insulin
glargine–based MDI against CSII in uns-
elected (except for study purposes) peo-
ple with type 1 diabetes, they cannot be
applied to “selected” people with type 1
diabetes who may have special indica-
tions to CSII, such as long duration of
disease with low insulin requirements or
hypoglycemia unawareness with fre-
quent, severe hypoglycemia on long-
acting insulin analog–based MDI (6).
Additional studies are required in these
groups of selected people with type 1 di-
abetes to establish the possible equiva-
lence or otherwise of insulin glargine–
based MDI against CSII with regard to
glycemic control and the incidence and
awareness of hypoglycemia.
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